Skip to main content
Pharmanutra logo

Pharmanutra — Investor Relations & Filings

Ticker · PHN ISIN · IT0005274094 LEI · 815600F8217BC7733697 XMIL Manufacturing
Open in API
Filings indexed 601 across all filing types
Latest filing 2025-03-24 AGM Information
Country IT Italy
Listing XMIL PHN

About Pharmanutra

http://www.pharmanutra.it

PharmaNutra is a company operating in the pharmaceutical and nutraceutical sectors, focused on the development and distribution of nutritional supplements and medical devices. Grounded in scientific research, the company creates innovative solutions for health and wellness. Its core activities center on addressing nutritional deficiencies, particularly iron, through proprietary functional ingredients and technologies. The product portfolio also extends to supporting muscle and joint health, sports nutrition, and applications across various therapeutic areas, including gynecology, orthopedics, hematology, and gastroenterology. The company emphasizes the development of effective and safe products supported by clinical evidence.

Recent filings

Filing Released Lang Actions
PHN_Relazione Illustrativa sull'unico punto all'ordine del giorno dell'Assemblea Straordinaria
AGM Information Classification · 1% confidence The document is titled "RELAZIONE ILLUSTRATIVA DEL CONSIGLIO DI AMMINISTRAZIONE SULL'UNICO PUNTO ALL'ORDINE DEL GIORNO DELL'ASSEMBLEA STRAORDINARIA DI PHARMANUTRA S.P.A." (Explanatory Report of the Board of Directors on the Sole Agenda Item of the Extraordinary Shareholders' Meeting of Pharmanutra S.p.A.). The content details proposed amendments to the company's bylaws (Statuto sociale) concerning meeting procedures (Articles 9, 10, 16, and 22) for an upcoming Extraordinary Shareholders' Meeting. This document serves as the official explanatory report accompanying the notice for a shareholder meeting, specifically detailing the rationale behind proposed changes to governance rules. This aligns best with documents related to shareholder meetings and governance structure changes. While it relates to an AGM/EGM, the core purpose is explaining proposed statutory changes, which is a key component of governance documentation, but the context of an 'Extraordinary Shareholders' Meeting' and the explanatory nature strongly suggests a document related to soliciting votes or providing information for that meeting. Given the options, 'Proxy Solicitation & Information Statement' (PSI) covers materials sent to shareholders to provide information for meetings. However, since this is a formal 'Relazione Illustrativa' (Explanatory Report) detailing proposed changes to the bylaws for an Extraordinary Meeting, it is highly specific. If the meeting were routine, it might be related to AGM-R, but since it's about changing the bylaws, it's a critical governance document. In many regulatory contexts, detailed explanatory reports for shareholder votes on governance changes fall under the broader scope of proxy materials or governance reports. Given the focus on amending the 'Statuto sociale' (Bylaws) for an Extraordinary Meeting, it is a fundamental governance document. Since it is an explanatory report for a specific meeting agenda item, it functions as a key piece of information provided to shareholders, making PSI a strong candidate, but it is also a detailed governance document. Comparing it to the definitions: It is not a DEF 14A (Remuneration), nor a DVA (Voting Results). It is an explanatory report for a meeting, which is the function of a PSI. It is also a detailed governance document. Given the explicit mention of the 'Assemblea Straordinaria' and the detailed explanation of proposed changes to the bylaws, it functions as the core informational document for that vote. I will classify it as PSI (Proxy Solicitation & Information Statement) as it provides the necessary information for shareholders to vote on the proposed changes.
2025-03-24 Italian
PHN Explanatory Memorandum on buy back
AGM Information Classification · 1% confidence The document is titled 'ILLUSTRATIVE REPORT OF THE BOARD OF DIRECTORS ON THE MATTERS ON THE AGENDA OF THE ORDINARY SHAREHOLDERS' MEETING...'. The core subject matter discussed extensively throughout the text is the 'Proposal for authorization to purchase and dispose of treasury shares'. This proposal is being presented to shareholders for approval at an upcoming meeting. Documents detailing proposals, reports, and information provided to shareholders ahead of a general meeting, especially those concerning corporate actions like share buybacks, are typically classified as Proxy Solicitation & Information Statements (PSI) or related to the AGM. Since this is a detailed report outlining the rationale, mechanics, and proposed resolutions for shareholder approval regarding treasury share transactions, it strongly aligns with the content expected in materials distributed to solicit votes for a meeting. While it is a report, its function is to inform the vote, making PSI a strong candidate. However, the document explicitly states it is a 'REPORT OF THE BOARD OF DIRECTORS' for the 'ORDINARY SHAREHOLDERS' MEETING'. Given the specific focus on the agenda items and the request for shareholder resolution, it is highly relevant to the AGM process. Since the content is a detailed report presented for a shareholder vote, and not just a general announcement of the meeting (AGM-R) or a proxy solicitation document (PSI), and it deals specifically with a transaction in own shares (POS), I must choose the most appropriate category. The content is a detailed proposal for the Board to execute share repurchases/disposals. This directly matches the definition of 'Transaction in Own Shares' (POS), which covers reports of the company buying back or selling its own shares. Although it is presented at an AGM context, the substance is the authorization for share repurchase, making POS the most specific fit for the *subject matter* being resolved upon, even if it's delivered via an AGM report structure. Given the options, POS is the most precise classification for the core topic being authorized.
2025-03-24 English
PHN Relazione illustrativa azioni proprie
AGM Information Classification · 1% confidence The document is titled "RELAZIONE ILLUSTRATIVA DEL CONSIGLIO DI AMMINISTRAZIONE SULLE MATERIE ALL'ORDINE DEL GIORNO DELL'ASSEMBLEA ORDINARIA..." (Explanatory Report of the Board of Directors on the Agenda Items of the Ordinary Shareholders' Meeting). The core subject matter, detailed in Point 4 of the agenda and throughout the text, is the proposal to authorize the purchase and disposal of own shares ('autorizzazione all'acquisto e alla disposizione di azioni ordinarie proprie'). This proposal is being presented to the Shareholders' Meeting for deliberation, as evidenced by the final resolution section. This type of explanatory report accompanying a shareholder meeting agenda, especially one dealing with corporate actions like share buybacks, is typically classified as related to the Annual General Meeting (AGM) process or a specific proxy/governance document. Since the document is a detailed explanatory report ('Relazione Illustrativa') presented to the shareholders for a vote on a specific corporate action (share repurchase), it strongly aligns with the materials presented during the AGM process. While it discusses share transactions (POS), the document's format is the formal report supporting the shareholder vote, making AGM-R the most appropriate classification for the presentation material itself, rather than just the transaction announcement.
2025-03-24 Italian
CS disponibilità relazioni illustrative || PR Notice of availability
AGM Information Classification · 1% confidence The document is a formal announcement (Informazione Regolamentata) from PharmaNutra S.p.A. dated March 24, 2025. The subject (Oggetto) is 'CS disponibilità relazioni illustrative PR Notice of availability'. The text explicitly states that the Explanatory Reports ('Relazione Illustrativa') for the upcoming Shareholders' Meeting (Assemblea degli Azionisti) are now available to the public at various locations. This structure—announcing the availability of required documentation for a meeting—is characteristic of a notice regarding proxy materials or meeting documentation. Since the document is announcing the availability of reports related to a future Shareholders' Meeting (which includes items like the buyback program report), it strongly aligns with the purpose of Proxy Solicitation & Information Statement materials, which often precede the actual meeting or voting results. However, the core action here is the *publication* of required documents for a meeting, which often falls under the scope of proxy materials (PSI) or, if it were just a generic announcement of publication without specific context, RPA. Given the context is explicitly about documents for the 'Assemblea degli Azionisti' (Shareholders' Meeting), PSI (Proxy Solicitation & Information Statement) is the most precise fit, as these documents are provided to solicit informed shareholder participation/voting. The document length (6851 chars) is substantial enough that it is not just a brief 'RPA' placeholder, but a substantive notice detailing what is available and where.
2025-03-24 Italian
Pharmanutra: Ferro sucrosomiale menzionato nelle linee guida WHO
Regulatory Filings Classification · 1% confidence The document is a formal announcement from an Italian company (Pharmanutra S.p.A.) dated March 24, 2025, identified by the header 'Informazione Regolamentata' (Regulated Information) and a specific identification number. The 'Oggetto' (Subject) is 'Pharmanutra: Ferro sucrosomiale menzionato nelle linee guida WHO' (Pharmanutra: Sucrosomial iron mentioned in WHO guidelines). The text details a significant development—the inclusion of their patented product component in World Health Organization guidelines. This type of announcement, which communicates material, non-financial, or general corporate news to the market via a regulatory channel (implied by the structure and 'Informazione Regolamentata' tag), fits best under the general 'Regulatory Filings' category (RNS) as it is not a specific financial report (10-K, IR, ER), a management change (MANG), or a dividend notice (DIV). It is a general corporate update disseminated through regulatory means.
2025-03-24 Italian
PHN Sucrosomial Iron mentioned in guidance WHO
Regulatory Filings Classification · 1% confidence The document is a formal announcement from PHARMANUTRA S.P.A. regarding its Sucrosomial Iron being mentioned in the World Health Organisation (WHO) Guidelines. The metadata indicates it is an 'Informazione Regolamentata' (Regulated Information) disseminated on March 24, 2025. The content is a press release detailing a significant event (recognition by WHO) rather than a full financial report (like 10-K or IR) or a transcript. Since it is a specific, material announcement that doesn't fit the definitions for earnings (ER), dividend (DIV), capital changes (CAP), or director dealings (DIRS), it falls best under the general 'Regulatory Filings' category (RNS) as a miscellaneous regulatory announcement, or potentially an Earnings Release (ER) if it were tied to financial results, but here it is purely operational/scientific news. Given the nature of announcing a specific, non-financial regulatory/guideline inclusion, RNS is the most appropriate general regulatory filing category for significant, non-standard announcements.
2025-03-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.